41 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
in the Territory where a Competent Authority may approve or determine pricing or pricing reimbursement for pharmaceutical products, such approval … reimbursement. The Licensee shall within [***] reimburse CRH in respect of any Patent Costs incurred up to and including the Effective Date as set forth
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
price for TNT119, the ability to obtain coverage and reimbursement, the ability to gain market share and whether Tenet owns the commercial rights … reimbursement for, new therapies in many underdeveloped markets.
Tenet has no experience in sales, marketing and distribution and may have to enter
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
from ValenzaBio for such costs and send invoice to ValenzaBio for reimbursement.
GENERAL ON PAYMENTS
10.1
Payment. Subject to the terms and conditions
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of Regulatory Approval, profitability (including pricing and reimbursement status achieved or likely to be achieved and amounts payable to Third Party licensors … with applicable Law (including NDAs, INDs, 510(k)s, 505(b)(2)s or their foreign equivalents, including where required for commercial sale, pricing and reimbursement
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, tolerability, convenience, price and the availability of reimbursement from government and other third-party payors relative to such competing products
8-K
EX-10.1
1ewtsj4n4 rv
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
7ybyo akd3t
4 Jun 24
Proxy related to merger
8:00am
PREM14A
msjj46ez7pqly9d0
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
n3t1yt342btd
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
ruu1okrqf gggh
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am